These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855 [TBL] [Abstract][Full Text] [Related]
23. The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL). Junevik K; Werlenius O; Hasselblom S; Jacobsson S; Nilsson-Ehle H; Andersson PO Ann Hematol; 2007 Feb; 86(2):89-94. PubMed ID: 17043777 [TBL] [Abstract][Full Text] [Related]
29. T-cell function in chronic lymphocytic leukaemia. Riches JC; Ramsay AG; Gribben JG Semin Cancer Biol; 2010 Dec; 20(6):431-8. PubMed ID: 20920582 [TBL] [Abstract][Full Text] [Related]
30. Perturbation of the normal immune system in patients with CLL. Forconi F; Moss P Blood; 2015 Jul; 126(5):573-81. PubMed ID: 26084672 [TBL] [Abstract][Full Text] [Related]
31. Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma. Winkelstein A; Jordan PS Clin Rev Allergy; 1992; 10(1-2):39-58. PubMed ID: 1606523 [No Abstract] [Full Text] [Related]
32. Disease-specific complications of chronic lymphocytic leukemia. Dearden C Hematology Am Soc Hematol Educ Program; 2008; ():450-6. PubMed ID: 19074125 [TBL] [Abstract][Full Text] [Related]
33. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Allegra A; Tonacci A; Musolino C; Pioggia G; Gangemi S Front Immunol; 2021; 12():738915. PubMed ID: 34759921 [TBL] [Abstract][Full Text] [Related]
34. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Sklenar I; Schiffman G; Jønsson V; Verhoef G; Birgens H; Boogaerts M; Ferrant A; Christensen BE; Hasle H; Drivsholm A Oncology; 1993; 50(6):466-77. PubMed ID: 8233289 [TBL] [Abstract][Full Text] [Related]
35. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Mellstedt H; Choudhury A Cancer Immunol Immunother; 2006 Feb; 55(2):210-20. PubMed ID: 15906026 [TBL] [Abstract][Full Text] [Related]
36. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Sampalo A; Brieva JA Leuk Lymphoma; 2002 Apr; 43(4):881-4. PubMed ID: 12153179 [TBL] [Abstract][Full Text] [Related]
37. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Jurlander J; Geisler CH; Hansen MM Eur J Haematol; 1994 Aug; 53(2):114-8. PubMed ID: 8088382 [TBL] [Abstract][Full Text] [Related]
39. [Correlations between secondary hypogammaglobulinaemia, infections and mortality and the need for preventive immunoglobulin replacement in patients with chronic lymphoid leukaemia]. Losonczy H; Nagy Á; Kosztolányi S; Tóth O; Csalódi R; Hussain A; Szomor Á Orv Hetil; 2019 Sep; 160(38):1487-1494. PubMed ID: 31537095 [TBL] [Abstract][Full Text] [Related]
40. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Boughton BJ; Jackson N; Lim S; Smith N Clin Lab Haematol; 1995 Mar; 17(1):75-80. PubMed ID: 7621634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]